Comparative Pharmacology
Head-to-head clinical analysis: HC 1 versus POKONZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HC 1 versus POKONZA.
HC #1 vs POKONZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown
POKONZA (ponazuril) is a triazine antiprotozoal agent that inhibits the mitochondrial electron transport chain at the cytochrome bc1 complex, disrupting the parasite's energy metabolism and leading to its death. It is active against apicomplexan parasites such as Toxoplasma gondii, Neospora caninum, and Sarcocystis neurona.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
Intravenous: 0.1 mg/kg every 8 hours for 28 consecutive days per 6-week cycle.
None Documented
None Documented
2–4 hours (terminal); prolonged in renal impairment.
Terminal elimination half-life 12-15 hours; clinically significant for once-daily dosing with steady-state achieved in 3-5 days
Renal: 90% as unchanged drug; fecal: 10%.
Primarily renal excretion (70-80% unchanged drug); biliary/fecal elimination accounts for 15-20%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid